EN ISO 10993-5-2009 en Biological evaluation of medical devices - Part 5 Tests for in vitro cytotoxicity《医疗器械的生物学评定 第5部分 体外细胞毒性测试》.pdf

《EN ISO 10993-5-2009 en Biological evaluation of medical devices - Part 5 Tests for in vitro cytotoxicity《医疗器械的生物学评定 第5部分 体外细胞毒性测试》.pdf》由会员分享，可在线阅读，更多相关《EN ISO 10993-5-2009 en Biological evaluation of medical devices - Part 5 Tests for in vitro cytotoxicity《医疗器械的生物学评定 第5部分 体外细胞毒性测试》.pdf（46页珍藏版）》请在麦多课文档分享上搜索。

1、BS EN ISO10993-5:2009ICS 11.100.20NO COPYING WITHOUT BSI PERMISSION EXCEPT AS PERMITTED BY COPYRIGHT LAWBRITISH STANDARDBiological evaluationof medical devicesPart 5: Tests for in vitro cytotoxicity(ISO 10993-5:2009)This British Standard was published under the authority of the Standards Policy and

2、Strategy Committee on 31 July2009. BSI 2009ISBN 978 0 580 58259 2Amendments/corrigenda issued since publicationDate CommentsBS EN ISO 10993-5:2009National forewordThis British Standard is the UK implementation of EN ISO 10993-5:2009. It supersedes BS EN ISO 10993-5:1999 which is withdrawn.The UK par

3、ticipation in its preparation was entrusted to Technical Committee CH/194, Biological evaluation of medical devices.A list of organizations represented on this committee can be obtained on request to its secretary.This publication does not purport to include all the necessary provisions of a contrac

4、t. Users are responsible for its correct application.Compliance with a British Standard cannot confer immunity from legal obligations.EUROPEAN STANDARDNORME EUROPENNEEUROPISCHE NORMEN ISO 10993-5June 2009ICS 11.100.20 Supersedes EN ISO 10993-5:1999 English VersionBiological evaluation of medical dev

5、ices - Part 5: Tests for invitro cytotoxicity (ISO 10993-5:2009)valuation biologique des dispositifs mdicaux - Partie 5:Essais concernant la cytotoxicit in vitro (ISO 10993-5:2009)Biologische Beurteilung von Medizinprodukten - Teil 5:Prfungen auf In-vitro-Zytotoxizitt (ISO 10993-5:2009)This European

6、 Standard was approved by CEN on 17 April 2009.CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this EuropeanStandard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concernin

7、g such nationalstandards may be obtained on application to the CEN Management Centre or to any CEN member.This European Standard exists in three official versions (English, French, German). A version in any other language made by translationunder the responsibility of a CEN member into its own langu

8、age and notified to the CEN Management Centre has the same status as theofficial versions.CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland,France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxem

9、bourg, Malta, Netherlands, Norway, Poland, Portugal,Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.EUROPEAN COMMITTEE FOR STANDARDIZATIONCOMIT EUROPEN DE NORMALISATIONEUROPISCHES KOMITEE FR NORMUNGManagement Centre: Avenue Marnix 17, B-1000 Brussels 2009 CEN All rights of

10、 exploitation in any form and by any means reservedworldwide for CEN national Members.Ref. No. EN ISO 10993-5:2009: EBS EN ISO 10993-5:2009EN ISO 10993-5:2009 (E) 3 Foreword This document (EN ISO 10993-5:2009) has been prepared by Technical Committee ISO/TC 194 “Biological evaluation of medical devi

11、ces“ in collaboration with Technical Committee CEN/TC 206 “Biological evaluation of medical devices” the secretariat of which is held by NEN. This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by Decemb

12、er 2009, and conflicting national standards shall be withdrawn at the latest by December 2009. Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN and/or CENELEC shall not be held responsible for identifying any or all such patent

13、 rights. This document supersedes EN ISO 10993-5:1999. This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EC Directives. For relationship with EC Directives, see informative Annex ZA

14、and ZB, which are integral parts of this document. According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France,

15、Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom. Endorsement notice The text of ISO 10993-5:2009 has been approved by CEN as EN ISO 10993-5:2

16、009 without any modifications. BS EN ISO 10993-5:2009EN ISO 10993-5:2009 (E) 4 Annex ZA (informative) Relationship between this International Standard and the Essential Requirements of EU Directive 93/42/EEC This International Standard has been prepared under a mandate given to CEN by the European C

17、ommission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 93/42/EEC on medical devices. Once this standard is cited in the Official Journal of the European Communities under that Directive and has been implemented as a

18、national standard in at least one Member State, compliance with the clauses of this standard given in Table ZA.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA regulations. Tabl

19、e ZA.1 Correspondence between this International Standard and Directive 93/42/EEC Clause(s)/sub-clause(s) of this International Standard Essential Requirements (ERs) of Directive 93/42/EEC Qualifying remarks/Notes 4, 5, 6, 7, 8, 9, 10 Annex I: 7.1, 7.2, 7.5 WARNING: Other requirements and other EU D

20、irectives may be applicable to the product(s) falling within the scope of this International standard. BS EN ISO 10993-5:2009EN ISO 10993-5:2009 (E) 5 Annex ZB (informative) Relationship between this International Standard and the Essential Requirements of EU Directive 90/385/EEC This International

21、Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of the New Approach Directive 90/385/EEC on active implantable medical devices. Once this standard is cited in the Off

22、icial Journal of the European Communities under that Directive and has been implemented as a national standard in at least one Member State, compliance with the clauses of this standard given in Table ZB.1 confers, within the limits of the scope of this standard, a presumption of conformity with the

23、 corresponding Essential Requirements of that Directive and associated EFTA regulations. Table ZB.1 Correspondence between this International Standard and Directive 90/385/EEC Clause(s)/sub-clause(s) of this International Standard Essential Requirements (ERs) of Directive 90/385/EEC Qualifying remar

24、ks/Notes 4, 5, 6, 7, 8, 9, 10 Annex I: 9 WARNING Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard. BS EN ISO 10993-5:2009ISO 10993-5:2009(E) ISO 2009 All rights reserved iiiContents Page Foreword iv Introduction . vi 1 Scope . 1

25、 2 Normative references . 1 3 Terms and definitions. 1 4 Sample and control preparation 2 4.1 General. 2 4.2 Preparation of liquid extracts of material. 3 4.3 Preparation of material for direct-contact tests 4 4.4 Preparation of controls 5 5 Cell lines 5 6 Culture medium. 5 7 Preparation of cell sto

26、ck culture . 6 8 Test procedures 6 8.1 Number of replicates 6 8.2 Test on extracts 6 8.3 Test by direct contact. 7 8.4 Test by indirect contact 7 8.5 Determination of cytotoxicity 9 9 Test report . 10 10 Assessment of results 11 Annex A (informative) Neutral red uptake (NRU) cytotoxicity test 12 Ann

27、ex B (informative) Colony formation cytotoxicity test. 19 Annex C (informative) MTT cytotoxicity test . 24 Annex D (informative) XTT cytotoxicity test 29 Bibliography . 34 BS EN ISO 10993-5:2009ISO 10993-5:2009(E) iv ISO 2009 All rights reservedForeword ISO (the International Organization for Standa

28、rdization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right t

29、o be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization. International Sta

30、ndards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2. The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an In

31、ternational Standard requires approval by at least 75 % of the member bodies casting a vote. Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. ISO 1099

32、3-5 was prepared by Technical Committee ISO/TC 194, Biological evaluation of medical devices. This third edition cancels and replaces the second edition (ISO 10993-5:1999) which has been technically revised. ISO 10993 consists of the following parts, under the general title Biological evaluation of

33、medical devices: Part 1: Evaluation and testing within a risk management process Part 2: Animal welfare requirements Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity Part 4: Selection of tests for interactions with blood Part 5: Tests for in vitro cytotoxicity Part 6: Tests

34、for local effects after implantation Part 7: Ethylene oxide sterilization residuals Part 9: Framework for identification and quantification of potential degradation products Part 10: Tests for irritation and skin sensitization Part 11: Tests for systemic toxicity Part 12: Sample preparation and refe

35、rence materials Part 13: Identification and quantification of degradation products from polymeric medical devices Part 14: Identification and quantification of degradation products from ceramics Part 15: Identification and quantification of degradation products from metals and alloys BS EN ISO 10993

36、-5:2009ISO 10993-5:2009(E) ISO 2009 All rights reserved v Part 16: Toxicokinetic study design for degradation products and leachables Part 17: Establishment of allowable limits for leachable substances Part 18: Chemical characterization of materials Part 19: Physico-chemical, morphological and topog

37、raphical characterization of materials Technical Specification Part 20: Principles and methods for immunotoxicology testing of medical devices Technical Specification BS EN ISO 10993-5:2009ISO 10993-5:2009(E) vi ISO 2009 All rights reservedIntroduction Due to the general applicability of in vitro cy

38、totoxicity tests and their widespread use in evaluating a large range of devices and materials, it is the purpose of this part of ISO 10993, rather than to specify a single test, to define a scheme for testing which requires decisions to be made in a series of steps. This should lead to the selectio

39、n of the most appropriate test. Three categories of test are listed: extract test, direct contact test, indirect contact test. The choice of one or more of these categories depends upon the nature of the sample to be evaluated, the potential site of use and the nature of the use. This choice then de

40、termines the details of the preparation of the samples to be tested, the preparation of the cultured cells, and the way in which the cells are exposed to the samples or their extracts. At the end of the exposure time, the evaluation of the presence and extent of the cytotoxic effect is undertaken. I

41、t is the intention of this part of ISO 10993 to leave open the choice of type of evaluation. Such a strategy makes available a battery of tests, which reflects the approach of many groups that advocate in vitro biological tests. The numerous methods used and endpoints measured in cytotoxicity determ

42、ination can be grouped into the following categories of evaluation: assessments of cell damage by morphological means; measurements of cell damage; measurements of cell growth; measurements of specific aspects of cellular metabolism. There are several means of producing results in each of these four

43、 categories. The investigator should be aware of the test categories and into which category a particular technique fits, in order that comparisons be able to be made with other results on similar devices or materials both at the intra- and interlaboratory level. Examples of quantitative test protoc

44、ols are given in annexes. Guidance for the interpretation of the results is given in this part of ISO 10993. BS EN ISO 10993-5:2009INTERNATIONAL STANDARD ISO 10993-5:2009(E) ISO 2009 All rights reserved 1Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity 1 Scope This pa

45、rt of ISO 10993 describes test methods to assess the in vitro cytotoxicity of medical devices. These methods specify the incubation of cultured cells in contact with a device and/or extracts of a device either directly or through diffusion. These methods are designed to determine the biological resp

46、onse of mammalian cells in vitro using appropriate biological parameters. 2 Normative references The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenc

47、ed document (including any amendments) applies. ISO 10993-1, Biological evaluation of medical devices Part 1: Evaluation and testing within a risk management system ISO 10993-12, Biological evaluation of medical devices Part 12: Sample preparation and reference materials 3 Terms and definitions For

48、the purposes of this document, the terms and definitions given in ISO 10993-1 and the following apply. 3.1 culture vessels vessels appropriate for cell culture including glass petri dishes, plastic culture flasks or plastic multiwells and microtitre plates NOTE These can be used interchangeably in t

49、hese methods provided that they meet the requirements of tissue culture grade and are suitable for use with mammalian cells. 3.2 positive control material material which, when tested in accordance with this part of ISO 10993, provides a reproducible cytotoxic response BS EN ISO 10993-5:2009ISO 10993-5:2009(E) 2 ISO 2009 All rights reservedNOTE The purpose of the positive control is to demonstrate an appropriate test system response. For example, an organotin-stabilized polyurethane1)has been us